NATCO Pharma to sell stake in Nativita and assets of Pharma division

NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord

Kimia Biosciences unveils new logo, new website

Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility

The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers

USFDA inspection at Alembic Pharmaceuticals Injectable Facility (F-3) at Karkhadi

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Zydus receives final approval from USFDA for two tablets

The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke